Agomab Therapeutics

Agomab Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: AGMB) developing novel disease-modifying therapies for fibro-inflammatory diseases, with an initial focus on chronic fibrotic indications of high unmet medical need such as Crohn's disease and idiopathic pulmonary fibrosis. Building on deep expertise in growth factor biology, Agomab advances a pipeline of small-molecule and antibody candidates targeting the pathways that drive tissue fibrosis and inflammation. Headquartered in Belgium with operations across Europe and the United States, the company was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network. As a biopharmaceutical company it publishes a corporate and investor-relations web presence rather than a public developer API surface; this profile captures its identity and public web properties for the network catalog.

Agomab Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Therapeutics, and Fibrosis.

Agomab Therapeutics’ developer surface includes engineering blog, product news, support, legal docs, and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalBiotechnologyTherapeuticsFibrosisHealthcareLife SciencesDrug Development

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/agomab-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Support

Support

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

Legal

Legal

Company 7

The organization behind the API

Website

About

Blog

News

Jobs

InvestorRelations

InvestorRelations

LinkedIn

Scroll for all 7

Other 2

Properties that don't map to a standard resource type

Science

Science

Pipeline

Pipeline

Source (apis.yml)

aid: agomab-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/agomab-therapeutics.png
name: Agomab Therapeutics
description: 'Agomab Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: AGMB) developing novel disease-modifying
  therapies for fibro-inflammatory diseases, with an initial focus on chronic fibrotic indications of high unmet medical need
  such as Crohn''s disease and idiopathic pulmonary fibrosis. Building on deep expertise in growth factor biology, Agomab
  advances a pipeline of small-molecule and antibody candidates targeting the pathways that drive tissue fibrosis and inflammation.
  Headquartered in Belgium with operations across Europe and the United States, the company was surfaced as a portfolio company
  of Canaan Partners and added to the API Evangelist network. As a biopharmaceutical company it publishes a corporate and
  investor-relations web presence rather than a public developer API surface; this profile captures its identity and public
  web properties for the network catalog.'
url: https://raw.githubusercontent.com/api-evangelist/agomab-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Therapeutics
- Fibrosis
- Healthcare
- Life Sciences
- Drug Development
apis: []
common:
- type: DomainSecurity
  url: security/agomab-therapeutics-domain-security.yml
- type: Website
  url: https://agomab.com/
- type: About
  url: https://agomab.com/about_us/
- type: Science
  url: https://agomab.com/growth_factor_biology/
- type: Pipeline
  url: https://agomab.com/pipeline/
- type: Blog
  url: https://agomab.com/news-events/
- type: News
  url: https://agomab.com/news-events/
- type: Support
  url: https://agomab.com/contact_us/
- type: Contact
  url: https://agomab.com/contact_us/
- type: Jobs
  url: https://agomab.com/careers/
- type: InvestorRelations
  url: https://ir.agomab.com/
- type: TermsOfService
  url: https://agomab.com/terms_of_use/
- type: Legal
  url: https://agomab.com/legal/
- type: LinkedIn
  url: https://www.linkedin.com/company/agomab-therapeutics/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence